Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) delivers vital blood and plasma management solutions to healthcare providers worldwide. This page serves as the definitive source for official company announcements, financial updates, and innovation milestones.
Access timely updates on earnings reports, regulatory clearances, and strategic partnerships that shape HAE's leadership in medical technology. Investors will find press releases covering product launches like advanced diagnostic systems, operational expansions, and initiatives enhancing transfusion safety standards.
Our curated news collection helps stakeholders monitor developments across HAE's three core segments: plasma collection technologies, blood center optimization tools, and hospital transfusion management systems. Bookmark this page for direct access to filings, executive commentary, and progress updates on life-saving healthcare solutions.
Haemonetics Corporation (NYSE: HAE) announced it has received CE mark certification for its VASCADE® vascular closure and VASCADE MVP® venous closure systems. This certification enables the company to launch these products in the European Union and other regions recognizing CE marking. The VASCADE system is tailored for small-bore femoral closure in various medical procedures, while VASCADE MVP is designed for mid-bore closures, particularly after cardiac ablation. Both systems aim to improve patient outcomes and hospital efficiency.
Haemonetics Corporation (NYSE: HAE) announced on August 29, 2022, a partnership with Epic, a major Electronic Health Record (EHR) provider, to integrate its SafeTrace Tx® blood bank information system into Epic's hospital network. SafeTrace Tx enhances transfusion management by ensuring patient safety and operational efficiency through comprehensive data management. This agreement aims to improve hospital transfusion processes amid ongoing staffing and blood supply challenges. Haemonetics continues to focus on innovative solutions to enhance patient care and optimize hospital operations.
Haemonetics Corporation (NYSE: HAE) announced that CEO Chris Simon will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:45 a.m. ET. Investors can access the live presentation via a webcast, with a replay available for 180 days post-event, starting at 12:00 p.m. ET. Haemonetics focuses on innovative medical products to enhance patient care and improve healthcare costs.
Haemonetics Corporation (NYSE: HAE) released its financial results for Q1 FY23, ending July 2, 2022. The results and additional analytical information are available on the company's Investor Relations website. A conference call is scheduled for August 10, 2022, at 8:00 a.m. EDT to discuss these results with investors and analysts. Participants can access the call via a teleconference link or live webcast. Earnings release and supplemental documents related to the quarter were also posted online for detailed review.
Haemonetics Corporation (NYSE: HAE) announced it will release its first quarter fiscal year 2023 financial results at 6:00 am EDT on August 10, 2022. A conference call for investors and analysts will follow at 8:00 am EDT on the same day. Participants can register to access the call and a live webcast will be available on the company's investor relations website. A replay of the call will be accessible for one year starting from 11:00 am EDT on August 10, 2022.
Haemonetics Corporation (NYSE: HAE) has officially launched operations at its new manufacturing Center of Excellence in Clinton, PA, covering 200,000 square feet. This facility enhances production capabilities for critical disposables and consumables across its Plasma and Hospital sectors. The site utilizes advanced technology and environmentally-friendly features, showcasing Haemonetics' commitment to operational excellence. With over 30 years in the Pittsburgh area, the company aims to improve patient outcomes while meeting growing demand.
Haemonetics Corporation (NYSE: HAE) will host its Investor Day on June 29, 2022, in Boston, starting at 10:00 AM EDT. This hybrid event allows for in-person attendance for capital markets professionals, while others can participate via a webcast. Attendees can engage with product demonstrations before the presentations. The Company aims to update stakeholders on strategies, market leadership in plasma and hospital sectors, and plans for financial growth through fiscal 2026. A replay and presentation materials will be available post-event.
Haemonetics Corporation (NYSE: HAE) has made its fourth quarter fiscal 2022 financial results available online, following the period ending April 2, 2022. A conference call will be held on May 10, 2022, at 8:00 a.m. EDT to discuss these results. Investors can access the earnings release, analytical tables, and supplemental information on the Investor Relations website. The earnings call will also be available for replay for one year after the event.
Haemonetics Corporation (NYSE: HAE) will host an Investor Day on June 29, 2022, at 10:00 AM EDT in Boston. The event aims to share insights on the Company’s long-term strategic plans, key initiatives, and financial outlook. It will be hybrid, allowing in-person attendance and a simultaneous webcast for remote participants. Registration is required via the Company's Investor Relations website. A replay and presentation materials will be available post-event on Haemonetics' website.
Haemonetics Corporation (NYSE: HAE) will publish its fourth quarter and fiscal year 2022 financial results on May 10, 2022, at 6:00 am EDT. An investor conference call for discussing these results will be held at 8:00 am EDT on the same day. Investors can access the call by dialing (877) 848-8880 for U.S. and Canada or (716) 335-9512 internationally, with Conference ID 5347317. A live webcast will also be available through Haemonetics' investor relations website, with a replay accessible for one year post-call.
FAQ
What is the current stock price of Haemonetics Mass (HAE)?
What is the market cap of Haemonetics Mass (HAE)?
